ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00925574
Recruitment Status : Completed
First Posted : June 22, 2009
Last Update Posted : September 5, 2017
Sponsor:
Information provided by (Responsible Party):
Centocor, Inc.

June 16, 2009
June 22, 2009
September 5, 2017
June 4, 2009
October 11, 2010   (Final data collection date for primary outcome measure)
Safety and tolerability of CNTO 1959 in healthy volunteers and patients with psoriasis. [ Time Frame: Assessments will occur at each study visit and up to 24 weeks following administration of study agent ]
Same as current
Complete list of historical versions of study NCT00925574 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics. [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Pharmacodynamics [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Immune Response [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Clinical Response [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Pharmacokinetics [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Pharmacodynamics [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Immune Response [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
  • Clinical Response [ Time Frame: Assessments will occur at study visits through 24 weeks following administration of study agent. ]
Not Provided
Not Provided
 
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects and in Subjects With Moderate to Severe Psoriasis
The purpose of this study is to evaluate the safety and how the body affects a drug (CNTO 1959) in healthy volunteers and in patients with psoriasis.
CNTO 1959 is an experimental drug. In this study, CNTO 1959 will be tested to see if it may be useful in treating psoriasis. This disease causes inflammation of skin and nails. This is a Randomized (study drug assigned by chance), Double-blind (neither physician nor patient knows the name of the assigned drug), Placebo-controlled study of the experimental drug CNTO 1959 in both healthy patients as well as patients with psoriasis. This study will compare the effects (both good and bad) of CNTO 1959 to those of placebo. The purpose of this study is to evaluate the safety and potential side effects of CNTO 1959 given to healthy volunteers and patients with moderate to severe psoriasis. In addition, the investigators will measure how much study drug is in the blood following a dose of CNTO 1959, and determine if the body makes antibodies to it. (An antibody is a protein made by the body in response to a foreign substance). Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure), and the occurrence and severity of adverse events. This is the first time that CNTO 1959 will be studied in humans. There will be 2 parts to this study. The first part of this study will involve healthy volunteers, and the second part of the study will involve patients with psoriasis. About 47 healthy volunteers and 24 patients with moderate to severe psoriasis will take part in the study. Enrollment for the healthy volunteer part is closed as of 23SEP09. CNTO 1959 will be administered as either an intravenous (IV) infusion or subcutaneous (SC) injection. Duration of participation may be up to 28 weeks.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Psoriasis
Drug: CNTO 1959; Placebo
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
71
Same as current
October 11, 2010
October 11, 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male or female with no clinically significant abnormalities and have a body weight of 50 to 100 kg (Enrollment of healthy volunteers closed on 23SEP09)
  • Patients with moderate to severe psoriasis and have a body weight not greater than 120 kg.

Exclusion Criteria:

  • Current or a history of any clinically significant medical illness or medical disorders the investigator considers should exclude the patient, including (but not limited to) cardiovascular disease, neuromuscular, hematological disease, respiratory disease, hepatic or GI disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
  • Known or recent history of alcohol or drug abuse
  • Major or traumatic surgery within 12 weeks of screening
  • Donated blood greater than 500 ml within 56 days of screening
  • Pregnant or nursing
  • Have recently received phototherapy or any systemic medications/treatments that could affect psoriasis
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00925574
CR015817
CNTO1959PSO1001
CR015817
No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Centocor, Inc.
Centocor, Inc.
Not Provided
Study Director: Centocor, Inc. Clinical Trial Centocor, Inc.
Centocor, Inc.
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP